The Affordable Care Act Gives Drugmakers A Boost: CMS

esilverman What hath the Affordable Care Act wrought? For drugmakers, there looks to be a big boost in spending on prescription medicines. Projected spending is forecast to ...

GlaxoSmithKline wins FDA ‘breakthrough’ tag for malaria treatment

Damian Garde GlaxoSmithKline has picked up the FDA's coveted "breakthrough therapy" designation for its investigative malaria candidate, news that could shave months off ...

Actelion gets second boost for Opsumit with EU approval

Eric Palmer The Swiss drugmaker said in a statement that the EC approved the drug for use by itself or in concert with another PAH drug. Actelion intends to begin selling it in Europe ...

Ariad returns Iclusig to market but with more restrictions and smaller patient pool

Eric Palmer Ariad Pharmaceuticals is back in the market with Iclusig. The FDA is allowing the Cambridge, MA-based company to again sell the leukemia drug, but with tighter restrictions ...

Most-recognized brands: Anti-infectives, December 2013

joshua.slatko The most-recognized anti-infective brand in North America is Cipro. The brand was most-recognized by 7 percent of physicians in a survey conducted by Brand Institute ...

Ariad storms back with an FDA nod to get Iclusig back on the U.S. market

Damian Garde Losing more than $ 2.5 billion in market value didn't kill Ariad Pharmaceuticals, and now the biotech is set to relaunch the once-spurned cancer drug Iclusig in the ...

Amarin is waiting till next year for an FDA decision on Vascepa, but investors are fine

Carly Helfand Amarin will have to wait until the new year to find out whether it's fish oil pill Vascepa will be approved for a wider indication. FiercePharma News

Study: Most Workers Satisfied With Pay-Benefits Balance

barbara.lempert New Research from EBRI: Most Workers Satisfied With Pay-Benefits Balance; Health Insurance Remains Key Job-Choice Factor   WASHINGTON, DC—Most workers are satisfied ...

Intrexon bets $26M on stem cells, teams up with troubled OvaScience

Damian Garde Intrexon, a Maryland biotech backed by billionaire RJ Kirk, has agreed to snap up San Diego regenerative medicine outfit for $ 26 million, and the company inked a separate ...

French competition watchdog slaps Merck, Reckitt for talking down Subutex generics

Tracy Staton European antitrust watchdogs have struck again. As Reuters reports, France's competition authority has fined Merck's Schering-Plough unit €15.3 million ($ ...

Doxil update: J&J strikes deal to manufacture Doxil itself at Ben Venue plant

Eric Palmer Janssen Pharmaceuticals, which has struggled to maintain supplies of its cancer drug Doxil since supplier Ben Venue Laboratories ran into FDA issues, may have landed on ...

Continuing Medical Education Deserves More Scrutiny: Study

esilverman At a time when increasing scrutiny is applied to funding for continuing medical education, a new study notes that relatively little is known about medical communications ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS